Special Reminder Due to adjustments in the WeChat public account mechanism, please click on the top “Instrument Information Network” → the upper right “…” → set as★ a star, otherwise you may not see our updates.
On June 12, XtalPi Technology (XtalPi Holdings, 2228.HK) announced the completion of its acquisition of the UK-based LiverpoolChiroChem (LCC) technology company. This acquisition will further enhance XtalPi’s “AI + Robotics” intelligent autonomous experimental platform in the field of chemical space exploration, better serving clients in new drug development, new material discovery, and high-value chemical sectors both domestically and internationally.
Dr. Paul Colbon, founder and CEO of LCC, stated: “In 2020, the research results of AI chemical robots from the University of Liverpool were featured on the cover of Nature magazine. Anthony Huxley (the company’s chemistry lead) and I are thrilled to see this concept being widely applied in the industry today. We look forward to collaborating with XtalPi Technology to explore broader chemical spaces using cutting-edge technologies like AI and robotics combined with high-quality data, helping clients find high-value molecules faster.”
“At the same time, our Scientific Advisory Board (SAB), including Dr. Chris Swain and Dr. Stevan Djuric, is also very excited about this collaboration—LCC’s proud achievements in chiral chemistry, if enhanced by innovative technologies like AI and robotics, will accelerate the healing of more people.”
Founded in 2014 at the University of Liverpool, LCC Technology has long been dedicated to the research and development of design and synthesis technologies for novel molecules, particularly new chiral molecules. The company’s PACE (Parallel Automated Chiral Engine) technology platform combines AI software with automation technology, enabling virtual screening of target molecules from a chiral chemical library of over a hundred million molecules, and efficiently completing synthesis with the help of automated equipment for physical testing. This platform has served several well-known multinational pharmaceutical companies.
Additionally, the chiral chemical molecular library and database accumulated by the company over the years is globally leading in molecular quality and diversity, providing high-quality data support for AI models exploring chiral molecular chemical spaces.
Furthermore, LCC Technology has developed a complete technical solution in the field of high-throughput, micro-scale molecular library construction, complementing the large-scale molecular library technology of XtalPi’s intelligent autonomous experimental platform.
Through strategic cooperation, incubation, joint research and development, and acquisitions, XtalPi Technology’s technical strength in chemical space exploration continues to grow, and its ability to serve overseas clients is further enhanced.
About XtalPi Technology:
XtalPi Technology (“XtalPi Holdings Limited”, stock abbreviation: XtalPi Holdings, 2228.HK) was founded in 2015 by three physicists from MIT. It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. The company combines first-principles calculations based on quantum physics, artificial intelligence, high-performance cloud computing, and scalable and standardized robotic automation to provide drug and material science R&D solutions and services for global and domestic companies in industries such as pharmaceuticals and materials science (including agricultural technology, energy, new chemicals, and cosmetics)..
| Copyright: Some materials in this article are sourced from the internet, and the copyright belongs to the original author. The views represent the author’s own and do not reflect the position of this account.| Reprint: Requires authorization from this account, please contact the editor.| Source: Instrument Information Network| Editor: Manman| Visual: Changyan ZhuziWeChat reading order has been revised~